Hope rises for cancer treatment as key drug gets U.S. approval

Drugs used to illustrate the story.
Drugs used to illustrate the story.

The U.S. Food and Drug Administration (FDA) on Wednesday granted breakthrough therapy designation to drug maker, AstraZeneca’s biggest new drug hope Durvalumab for the treatment in bladder cancer.

The experimental medicine is a “PD-L1’’ therapy that fights cancer by boosting the immune system.

The breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.

The drug, Durvalumab, is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers.

The drug is competing with rival products made by Bristol-Myers Squibb, Merck and Roche.

(Reuters/NAN)

Support PREMIUM TIMES' journalism of integrity and credibility

 

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate


NEVER MISS A THING AGAIN! Subscribe to our newsletter

* indicates required

DOWNLOAD THE PREMIUM TIMES MOBILE APP

Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

TEXT AD: New Discovery! Click Here To See A Miracle Device That Can Cure DIABETES, BLOOD PRESSURE, STROKE, ARTHRITIS, PAINS, OBESITY And 50 Other CHRONIC DISEASES Without Drugs Or Herbs.. Click Here Now To See It


All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.